Tert-Butyl2-(2-(2-Amino-2-Cyclohexylacetamido)-3,3-Dimethylbutanoyl)-Octahydrocyclopenta[C]Pyrrole-1-Carboxylate

In the multi-kilogram synthesis of the macrocyclic HCV NS3/4A protease inhibitor Simeprevir (OLYSIO®), the protected dipeptide Tert-Butyl 2‑(2‑(2‑Amino‑2‑cyclohexylacetamido)‑3,3‑dimethylbutanoyl)‑octahydrocyclopenta[c]pyrrole‑1‑carboxylate serves as the pivotal P2–P3 intermediate after the primary amide bond has been formed between cyclohexylglycine and tert‑leucine. The manufacturing process normally couples the free‑base amine of this intermediate with the activated P1‑acylated octahydrocyclopenta[c]pyrrole‑1‑carboxylic acid fragment using a phosphonium or aminium salt‑type activator, most frequently HATU (CAS 148893‑10‑1), in the presence of 2.5 – 3.0 equivalent of N,N‑diisopropylethylamine (DIPEA) in anhydrous N,N‑dimethylformamide at a controlled jacket temperature of 0 °C to 5 °C. The stoichiometry of the coupling partner is typically adjusted to 1.05 – 1.2 eq relative to the free amine, and the conversion is followed by offline reversed‑phase HPLC monitoring (C18 column, acetonitrile/0.1 % trifluoroacetic acid gradient, UV at 215 nm). Because the amino group is unprotected, the substrate is acutely hygroscopic and susceptible to adventitious oxidation; therefore all addition and dissolution operations are executed in a glove‑box or under argon‑blanketed Schlenk‑line conditions with rigorously dried solvent (Karl Fischer titration ≤ 50 ppm water). After aqueous work‑up the crude amide product is ordinarily purified by silica gel flash chromatography (ethyl acetate/n‑heptane gradients) where the front‑running diastereomerically enriched fraction is collected, and enantiomeric purity is verified by chiral HPLC on an amylose‑based column (Chiralpak IA, eluent n‑hexane/2‑propanol 80:20 v/v) against a reference co‑crystal standard. In campaigns compliant with ICH Q7 (GMP for Active Pharmaceutical Ingredients), the batch release specification for this amine intermediate includes assay by HPLC (≥ 98.0 area‑%), individual unknown impurity ≤ 0.15 %, residual DMF ≤ 880 ppm per USP <467> Option 1, and the diastereomer ratio determined by capillary electrophoresis to guarantee the integrity of the four stereocenters. When the protected intermediate is carried into the final coupling stage, subsequent global deprotection with trifluoroacetic acid/triisopropylsilane/water (95:2.5:2.5 v/v/v) removes the Boc and tert‑butyl ester groups without epimerization of the P2 α‑carbon, provided the cleavage is quenched within 3 h at 20 ± 2 °C and the product is isolated by methyl tert‑butyl ether trituration. The final API, Simeprevir, is then obtained after macrocyclisation and sulfonamide coupling, and the intermediate’s performance in this sequence is directly linked to crystal‑engineering attributes of the final formulated sodium salt monohydrate.

What Analytical Demands Arise When This Intermediate Is Manufactured as an ANDA Starting Material?

Under an abbreviated new drug application (ANDA) for generic Simeprevir, this amine intermediate is frequently designated as the regulatory starting material (RSM) in accordance with ICH Q11 and FDA’s guidance “Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) – Questions and Answers”. Justifying an RSM that still carries a free amino group demands a thoroughly documented control strategy that maps every potential chiral and chemical impurity back to the downstream steps. Beyond the core diastereomers arising from the octahydrocyclopenta[c]pyrrole motif (enantiomers of the (1R,2R,5S)‑configured lactam‑fused bicyclic core), the process impurity profile includes oxazolone formation upon activation of the contiguous cyclohexylglycine‑tert‑leucine motif, and traces of des‑cyclohexyl by‑products generated during the initial peptide‑bond construction. Typical HPLC specifications, following USP general chapter 621 guidelines for gradient elution, demand a resolving power (R_s) ≥ 2.0 between the desired (S,S,S,R)‑diastereomer and the (S,R,S,R)‑epimer at relative retention time 1.12. In a production‑scale 100 L jacketed glass reactor (Büchi glass reactor equipped with Hastelloy component‑wetted parts), the intermediate is isolated by concentration under reduced pressure (50 mbar, bath 35 °C) followed by precipitation from methylcyclohexane/tetrahydrofuran, and the solid is dried in a conical vacuum drier set to 40 °C for 18 h to meet residual solvent thresholds for Class 2 solvents — tetrahydrofuran ≤ 720 ppm, dichloromethane ≤ 600 ppm. When the generic route avoids the originator’s late‑stage chromatography, the reliance on this intermediate’s purity becomes critical; a single‑impurity spike above 0.05 % for the (1S,2S,5R)‑octahydrocyclopenta[c]pyrrole diastereomer causes the final Simeprevir to fail the optical purity criterion of [α]_D²⁰ = −44° to −48° (c = 0.5, methanol), necessitating recrystallisation‑driven rejection of a complete batch.

Chiral Scaffold for Structure–Activity Relationship (SAR) Elaboration in Macrocyclic NS3/4A Inhibitors

Medicinal chemistry programs that explore non‑covalent P2‑substituent variations rely on this fully protected dipeptide as a versatile protected handle because the simultaneous presence of the N‑terminal free amine, the tert‑butyl ester, and the octahydrocyclopenta[c]pyrrole scaffold allows parallel diversification at three vectors without installing orthogonal protecting groups. In a typical SAR platform, the amine is acylated with diverse heterocyclic carboxylic acids (e.g., 4‑aminothiazole‑2‑carboxylic acid or quinoline‑4‑carboxylic acid derivatives) using propylphosphonic anhydride (T3P) at 40 °C in ethyl acetate, and the resulting diastereomerically pure library members are evaluated for inhibition constants (K_i) in fluorescence‑based enzymatic assays against genotype‑1b NS3/4A protease (resonance energy transfer substrate Ac‑DED(EDANS)‑EEAbu‑ψ[COO]‑ASK(DABCYL)‑NH₂). Published hits are often correlated with calculated polar surface area and lipophilicity (clog P measured by the shake‑flask method at pH 7.4), but the fidelity of SAR interpretation hinges on the absence of racemisation during library synthesis; hence each synthesis block is validated by chiral SFC analysis (Chiralpak IG‑3, CO₂/methanol 70:30, 2.5 mL/min) before submission to the screening cascade. This intermediate has also been instrumental in probing the function of the octahydrocyclopenta[c]pyrrole ring on permeability as measured in Caco‑2 cell monolayers (P_app A‑to‑B ≥ 10 × 10⁻⁶ cm/s being a desired threshold). The material is however sensitive to prolonged storage in solution: partial amide‑bond hydrolysis was observed after 72 h at 40 °C/75 % RH, indicating that DMSO‑stock solutions must be freshly prepared before each assay plate run.

When the octahydrocyclopenta[c]pyrrole skeleton is required as a rigid bicyclic analog of proline in non‑HCV targets, the same compound serves as a precursor for ring opening or further functionalisation. Reductive opening of the pyrrolidine ring with lithium aluminium hydride (2.2 eq in tetrahydrofuran, reflux 6 h) yields the corresponding 2‑substituted cyclopentyl‑methylamine derivative, a transformation that proceeds without erosion of the P1‑embedded stereocenter if the reduction is quenched by sequential dropwise addition of water, 15 % aqueous sodium hydroxide, and water (Fieser work‑up). Subsequent N‑sulfonamide formation then generates mimics of the catalytic serine‑trapping warhead that have been evaluated as inhibitors of rhomboid proteases and the SARS‑CoV‑2 3CL protease. Because published data for this specific configuration is limited, controlled experiments with ¹⁵N‑labeled intermediates and HSQC correlation are recommended to unequivocally assign the stereochemical outcome. In all these derived applications, retaining the tert‑butyl ester until the last synthetic step minimizes diketopiperazine formation that otherwise becomes problematic when the corresponding free acid is stored for more than 48 h in solvents with a dielectric constant above 20.

When Precise Control of Acid‑Labile Protecting‑Group Cascade Determines Final API Oligomeric Content

For the deprotection marathon that converts this doubly protected intermediate into the free‑acid amine hydrochloride prior to macrocyclisation, the temperature window and water activity are not merely convenient values but operational boundaries dictated by the pseudo‑first‑order kinetics of tert‑butyl ester cleavage versus acid‑catalysed amide hydrolysis. Calorimetric data (reaction calorimeter RC1e, Mettler‑Toledo) obtained on 50 g scale with neat trifluoroacetic acid shows a heat‑flow onset of −185 W/kg when the substrate is dosed at once; controlled‑rate addition (syringe pump, 0.5 mL/min into a 10 °C pre‑cooled mixture) maintains the exotherm below −50 W/kg and eliminates local hot spots that would generate des‑cyclohexylglycine amide detectable by LC‑TOF as the [M+H]⁺ = 452.2 species. After 1.5 h of stirring, the deprotected free‑acid amine is precipitated into chilled methyl tert‑butyl ether (0 °C, 10 vol) that has been pre‑dried over molecular sieves 4 Å; the slurry must be filtered under nitrogen within 30 min because the hydrochloride salt is deliquescent and absorbs atmospheric moisture to form a gum that entrains trifluoroacetic acid residues. Karl Fischer titration of the dried filter cake must not exceed 0.5 % water before it is engaged in the macrolactamisation mediated by diphenylphosphoryl azide and 2,4,6‑collidine. In production compliance, the entire deprotection‑precipitation‑filtration sequence is classified as a “key processing step” under ICH Q8(R2) Annex IV, which triggers at‑line PAT monitoring of the pH of the aqueous quenching stream (pH probe in the flow cell, target 6.8 – 7.2 after neutralisation with 10 % sodium bicarbonate) to confirm complete removal of fluorinated acids.